https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
62 logMar (SD 0.68; p less then 0.0001) and 401.04 μm (SD 257.5), respectively. The mean follow-up (FU) period was 47.8 months (min 12-max 12. At 12 months, the mean BCVA and CMT had significantly improved to 0.62 logMar (SD 0.68; p less then 0.0001) and 401.04 . Conclusion Intravitreal Ranibizumab and/or dexamethasone injections were found to be effective at inducing a long-lasting improvement of BCVA and CMT in a real-life clinical setting. A safety profile similar to that already well-established in Ranibizumab and dexa
Like
Comment
Share
